PROF

In October 2026, Profound Medical reported strong preliminary unaudited third-quarter 2026 revenue, expected between $9.8 million and $10.0 million, significantly exceeding analyst consensus and representing an 85% to 89% year-over-year increase, which triggered a stock rally and an anticipated gross margin over 70%. Also in October 2026, Wall Street Zen upgraded Profound Medical from a 'sell' to a 'hold' rating, and the company entered a co-education agreement with Telix Pharmaceuticals to advance PSMA-informed prostate care. In September 2026, Profound Medical participated in Lake Street's 10th Annual Best Ideas Growth Conference and strengthened its executive leadership team with the appointment of Richard Fabian as President. In August 2026, Profound introduced new real-time interventional MRI software and reported its Q2 2026 earnings, with an adjusted loss of $0.26 per share and revenue of $2.48 million, both missing analyst estimates. In July 2026, Raymond James Financial upgraded Profound Medical from an 'outperform' to a 'strong-buy' rating with an $11.00 target price. The company released its Q1 2026 earnings in May 2026.